There are a variety of different mutations that can underlie hereditary retinal dystrophy. Thanks to the development of modern molecular genetic testing methods, the genetic cause can nowadays be identified in the majority of cases. An innovative gene therapy is available for patients with retinal dystrophy due to biallelic RPE65 mutations.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- PancNEN, PancNET & PancNEC
Neuroendocrine tumors of the pancreas
- Heart failure
Interventional treatment of the tricuspid valve
- Lipoprotein(a)
Current and future treatment options
- Lichen sclerosus
Topical corticosteroids still the first choice
- Breast Cancer
On the trail of triple-negative breast cancer
- Headache treatment
The therapy of migraine
- Sleep disorders in old age
Recognize insomnia, treat it and avoid cognition disorders
- From symptom to diagnosis